Want to join the conversation?
$PDCO's 3Q16 Animal Health segment sales more than doubled YoverY on a constant currency basis. Sales in the legacy companion animal business, excluding revenue from the acquisition and the impact of the shift in veterinary diagnostic vendor relationships improved 6.2% in constant currency. US companion animal was strong, expanded by more than 11%.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?